12 months pre-IL-5 treatment | Mean | 12 months IL-5 treatment | Mean | P value | |
Exacerbations | 160 | 7.6 | 18 | 0.8 | p<0.001 |
Exacerbations—inpatient | 16 | 0.76 | 5 | 0.23 | p=0.016 |
Bed days | 128 | 6.09 | 35 | 1.6 | p=0.017 |
Maintenance steroid dose | 11.7 mg | 3.9 mg | p<0.001 | ||
ACQ Score | 2.8 | 0.9 | p<0.001 |
Exacerbations = number of recorded exacerbations (oral corticosteroid treatment/increase in maintenance oral corticosteroid dose for management) requiring specialist respiratory review but not requiring hospitalisation.
Exacerbations—inpatient = recorded exacerbations (increased asthma symptoms requiring antibiotic or corticosteroid treatment) requiring inpatient hospital treatment of at least 1 day.
Bed days = total number of days of hospital inpatient treatment due to exacerbation.
Maintenance steroid dose = average daily dose of oral corticosteroid required to maintain asthma symptom control. ACQ Score = Asthma Control Questionnaire measure of asthma symptom severity, range 1–6.
12 months pre IL-5 treatment = total number of events recorded within 12 months prior to starting IL-5 treatment. 12 months IL-5 treatment = total number of events recorded in the 12 months following commencement of IL-5 inhibitor treatment.
Mean = average number of documented events/treatment measure changes per patient during the stated time period.
p = P value probability significance measure.